

# Improving the health of veterans with chronic kidney disease

<b>Submission date</b> 25/02/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 15/03/2022	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 23/02/2024	<b>Condition category</b> Urological and Genital Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Background and study aims:

Sodium glucose co-transport 2 inhibitors (SGLT2i) are a class of drugs approved for the treatment of type 2 diabetes. Numerous studies have been published showing SGLT2i improves outcomes in chronic kidney disease (CKD) patients. CKD means your kidneys are damaged and can't filter blood the way they should. The main risk factors for developing kidney disease are diabetes, high blood pressure, heart disease, and a family history of kidney failure. The aim of this study is to improve the health of veterans with CKD by evaluating the effectiveness of a targeted pharmacy intervention in improving the rate of SGLT2i initiation among eligible patients.

Who can participate?

Veterans with chronic kidney disease who are candidates for SGLT2i therapy. These patients will be identified through an existing dashboard created by the VA.

What does the study involve?

Eligible patients will be mailed a letter outlining the benefits of starting SGLT2i therapy. Then, a care team member will contact the patient and offer a pharmacy consultation to initiate the medication. After reviewing criteria and discussing the risks and benefits with the Veteran, the pharmacist will initiate the appropriate dose of SGLT2i. Notification of the drug change will be sent to the patient's primary care provider. The pharmacist will schedule follow up labs 3 months after drug initiation and provide a phone number to Veterans to contact the pharmacist for future questions or to report adverse events. Labs at 3 months will be reviewed by the program's medical assistant. The Veteran will be contacted by letter with a summary of their lab results (sent by medical assistant) and reminded of the contact number. Any issues with labs will be flagged to the pharmacist to be addressed with the Veteran.

What are the possible benefits and risks of participating?

Benefits include improved CKD, cardiovascular, and other health outcomes, as well as decreased mortality. In trials, the incidence of hypoglycemia or other adverse events did not differ between SGLT2i treatment and control arms. Risks include any potential adverse events to SGLT2i, such as diabetic ketoacidosis, urinary tract infections, etc.

Where is the study run from?  
The Minneapolis VA Health Care System (USA)

When is the study starting and how long is it expected to run for?  
February 2022 to May 2024

Who is funding the study?  
US Veterans Association (USA)

Who is the main contact?  
Areef Ishani, MD, Areef.Ishani@va.gov

## Contact information

**Type(s)**  
Principal investigator

**Contact name**  
Dr Areef Ishani

**Contact details**  
1 Veterans Dr  
Minneapolis  
United States of America  
55417  
+1 612-467-4431  
Areef.Ishani@va.gov

**Type(s)**  
Public

**Contact name**  
Dr Areef Ishani

**Contact details**  
1 Veterans Dr  
Minneapolis  
United States of America  
55417  
+1 612-467-4431  
Areef.Ishani@va.gov

**Type(s)**  
Scientific

**Contact name**  
Dr Areef Ishani

**Contact details**

1 Veterans Dr  
Minneapolis  
United States of America  
55417  
+1 612-467-4431  
Areef.Ishani@va.gov

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

Nil known

## Study information

### Scientific Title

Evaluating the implementation of targeted pharmacy services to enhance the uptake of SGLT2i among veterans with chronic kidney disease (CKD)

### Study objectives

Patients that receive a targeted pharmacy intervention will have higher rates of SGLT2i initiation than those receiving usual care

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 26/01/2022, Minneapolis VA Health Care System (1 Veterans Dr, Minneapolis, MN, 55417, USA; +1 612-467-5655; julie.toth@va.gov), ref: n/a

### Study design

Multicenter interventional non randomised study

### Primary study design

Interventional

### Study type(s)

Prevention

### Health condition(s) or problem(s) studied

Chronic kidney disease

### Interventions

Using an established VA dashboard that identifies chronic kidney disease patients that are candidates for SGLT2i therapy, half of eligible patients will be sent a letter informing them of the benefits of this medication (the letter will be sent to patients whose social security number ends with an odd digit). A medical assistant will then reach out to those patients and offer to schedule a consultation with one of two intervention pharmacists. The pharmacist will review the patients' charts and ensure they meet necessary criteria for initiating the drug and no exclusion criteria exist. After reviewing criteria and discussing the risks and benefits with the Veteran, the pharmacist will initiate the appropriate dose of SGLT2i. Notification of the drug change will be sent to the patient's primary care provider. The pharmacist will schedule follow up labs 3 months after drug initiation and provide a phone number to Veterans to contact the pharmacist for future questions or to report adverse events. Labs at 3 months will be reviewed by the program's medical assistant.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

SGLT2 inhibitors

**Primary outcome(s)**

SGLT2i initiation will be tracked quarterly by assessing the presence of SGLT2 inhibitors on active medication lists in the electronic health record

**Key secondary outcome(s))**

1. Reach: Proportion of eligible patients being reached in each intervention assessed quarterly by data collected through the tracking app that has been developed to monitor patient outreach
2. Fidelity: Measured using an intervention tracking app assessed quarterly by data collected through the tracking app that has been developed to monitor patient outreach
3. Acceptability: Patient perception of starting the medication will be measured at the end of year one and the end of year two through semi-structured one-on-one qualitative interviews with patients

**Completion date**

01/01/2026

**Eligibility****Key inclusion criteria**

1. CKD (defined as eGFR  $\geq 25$  and eGFR  $< 60 \times 2$ )
2. Type 2 Diabetes (defined as either ICD9/10 code of Type 2 DM or most recent A1c  $\geq 7$ )
3. Must have active Metformin or (not on Metformin and has a Metformin allergy)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Type 1 diabetes
2. Taking SGLT-2 or GLP-1
3. SGLT2 allergy
4. On dialysis
5. Have a diagnosis of Pancreatic Cancer or Pancreatitis

**Date of first enrolment**

01/03/2022

**Date of final enrolment**

01/01/2025

## **Locations**

**Countries of recruitment**

United States of America

**Study participating centre**

**Minneapolis VA Health Care System**

1 Veterans Dr

Minneapolis

United States of America

55417

## **Sponsor information**

**Organisation**

Minneapolis VA Health Care System

**ROR**

<https://ror.org/02ry60714>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

U.S. Department of Veterans Affairs

**Alternative Name(s)**

Department of Veterans Affairs, United States Department of Veterans Affairs, US Department of Veterans Affairs, U.S. Dept. of Veterans Affairs, Veterans Affairs, Veterans Affairs Department, VA, USDVA

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United States of America

## Results and Publications

**Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date

**IPD sharing plan summary**

Data sharing statement to be made available at a later date

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		05/01/2024	08/01/2024	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes